Izun Pharmaceuticals
Jonathan Kalman is the founder and CEO of Dion Holding Ltd, which invests in early-stage Israeli technology companies with an emphasis on biopharma and medical devices. Jonathan was a member of the Board of Directors of Neuroderm (NDRM) from November 2014 until its acquisition by Mitsubishi Tanabe Pharma Corporation in October 2017 for $1.1 Billion.
Jonathan is currently a director of Revelator Ltd., a leading supplier of data services for today’s digital rights business. He is also on the board of directors of The Jerusalem Print Workshop, a non-profit art center dedicated to the advancement of the graphic arts in Israel.
This person is not in any teams
This person is not in any offices
Izun Pharmaceuticals
Izun Pharmaceuticals develops non-steroidal topical oral anti-inflammatory therapies for periodontal treatments.